BC
PRVB

Bridgefront Capital’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Bridgefront Capital’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,725
Closed -$107K – 730
2021
Q2 		$107K Buy
+12,725
New +$103K 0.04% 550

Other funds holding PRVB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sessa Capital
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
DCM
DG Capital Management New York $475M AUM 36.12% 1-Year Est. Return

Bridgefront Capital's PRVB Position: Q3 2021 in Review

Bridgefront Capital sold out of Provention Bio, Inc. Common Stock (PRVB) in Q3 2021, closing a stake of 12,725 shares — an estimated $107K sold.

Bridgefront Capital first reported a position in PRVB in Q2 2021 and held it in 1 quarter. The position peaked at $107K in Q2 2021. 115 funds tracked by Wall St. Rank hold PRVB as of Q3 2021.

  • Bridgefront Capital reported no remaining Provention Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Bridgefront Capital sold 12,725 Provention Bio, Inc. Common Stock shares in Q3 2021, an estimated $107K.
  • Bridgefront Capital first reported a position in Provention Bio, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Bridgefront Capital's Provention Bio, Inc. Common Stock position peaked at $107K in Q2 2021.
  • 115 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q3 2021.

Based on Bridgefront Capital's 13F filing for Q3 2021, filed 12 Nov 2021.